Core Viewpoint - The company is expected to return to a growth trajectory in 2025, driven by the recovery in demand from pharmaceutical clients and the domestic supply chain for insulin and GLP-1, maintaining a "Buy" rating [1][4]. Financial Performance - In 1H25, the company reported revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 309 million, 44 million, and 35 million yuan respectively, representing year-on-year increases of 9%, 18%, and 42% [1]. - For 2Q25, the figures were 163 million, 25 million, and 21 million yuan, showing year-on-year changes of +4%, -4%, and 0% [1]. Product Development and Market Expansion - The pharmaceutical rubber stopper segment showed orderly recovery with a projected double-digit revenue growth for the full year, achieving 310 million yuan in 1H25, a 9% year-on-year increase, with a gross margin of 39.4% [1]. - The company has a robust pipeline with 1,674 and 1,528 authorized projects for film-coated and conventional stoppers respectively, indicating an 8% and 6% increase from the end of 2024 [1]. - The company is entering the domestic supply chain for insulin through cartridge components, with expected revenue contributions starting in 2025, including a significant order of 200 million piston components from Ganli Pharmaceutical [2]. Capacity Expansion Initiatives - The company is developing the "Qihang Workshop" to expand its product offerings, including insulin components and pre-filled components, with planned capacities of 1.5 billion piston caps and 10 million COC/COP components [3]. - The company is also relocating and expanding its Chongqing factory to accelerate the aluminum cap project and enhance production capacity in the western market [3]. Valuation and Target Price - The company has increased its capital expenditure assumptions, projecting net profits attributable to shareholders of 110 million, 130 million, and 160 million yuan for 2025-2027 [4]. - A price-to-earnings ratio of 60x is assigned for 2025, with a target price of 39.46 yuan, reflecting a premium due to ongoing order fulfillment and new market entries [4].

证券研究报告 华兰股份 (301093 CH) 主业稳健增长，期待卡式瓶组件起量 | 华泰研究 | | | 中报点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2025 年 | 8 月 | 27 日│中国内地 | 医疗器械 | 目标价(人民币): | 39.46 | 公司公告 1H25 收入、归母净利、扣非净利 3.09、0.44、0.35 亿元（+9%、 +18%、+42% yoy），其中 2Q25 收入、归母净利、扣非净利 1.63、0.25、 0.21 亿元（+4%、-4%、-0% yoy）。随着药企客户需求恢复，我们预计 2025 年公司重回增长轨道，此外胰岛素与 GLP-1 供应链国产化有望带来收入利 润弹性，维持"买入"评级。 药用胶塞上半年有序恢复，全年收入有望双位数增长 1H25 收入 3.1 亿元（+9% yoy），毛利率 39.4%（同比基本持平），其中 常规胶塞收入同比增长 8%、覆膜胶塞收入同比增长 9%。1H25 公司在手授 权项目覆膜、常规胶塞分别 1674、1528 个（较 2024 年末增长 8%、6% ...